AstraZeneca
oncology total revenue growth driven by differentiated portfolio and new indication launches oncology key dynamics driven by global demand growth recovery strong uptake offset by flattening testing rates and in us driven by global launch acceleration revenues driven by continued her low bolus topaz strong growth offset by in us following maleate tablet approval strong global launch momentum new indications maleate tablet for | AstraZeneca
Company
Deck Type
Deck date
April 2023
Slide
14 of 41
Similar slides by AstraZeneca
Results
November 2023
Results
July 2023
Results
February 2023
Related slides by other companies
Results
November 2023
Investor Presentation
March 2014
Investor Presentation
February 2023
Results
April 2023
Other recent decks by AstraZeneca
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io